Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 Read more about Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego Read more about Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany Read more about Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 Read more about Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma Read more about Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma Read more about Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
Lilly Statement on Mounjaro® (tirzepatide) U.S. International Trade Commission Complaint Read more about Lilly Statement on Mounjaro® (tirzepatide) U.S. International Trade Commission Complaint
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Read more about Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
Lilly Welcomes Request from Senators About Insulin Affordability Programs Read more about Lilly Welcomes Request from Senators About Insulin Affordability Programs
